Camostat

Overview

Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19. Camostat mesylate was first approved in Japan in January 2006.

Indication

用于慢性胰腺炎的急性症状缓解。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Effect Camostat for Kidney Protection in Chronic Kidney Disease	2025/01/27	NCT06794593	Phase 2	Recruiting	Odense University Hospital
Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation	2022/07/26	NCT05474664	Phase 2	Completed	Seoul National University Hospital
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients	2021/01/29	NCT04730206	Phase 3	Terminated	KU Leuven
Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals	2020/12/23	NCT04681430	Phase 2	Completed	Heinrich-Heine University, Duesseldorf
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol	2020/12/10	NCT04662086	Phase 2	Completed	Stanford University
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol	2020/12/10	NCT04662073	Phase 2	Terminated	Stanford University
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)	2020/12/08	NCT04657497	Phase 3	Completed	Ono Pharmaceutical Co. Ltd
Camostat With Bicalutamide for COVID-19	2020/12/03	NCT04652765	Phase 1	Terminated	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Potential of Camostat in COVID-19	2020/11/12	NCT04625114	Phase 2	Terminated	University Hospital, Ghent
CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients	2020/10/29	NCT04608266	Phase 3	Terminated	Assistance Publique - Hôpitaux de Paris

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access